Richter Signs a License Agreement with Hikma to Commercialize Denosumab, a Proposed Biosimilar of Prolia and Xgeva in the US
Shots:
- Richter is eligible to receive up front along with milestones for development stages & is responsible for the development of the products & conduct both P-I & III studies along with supply finished commercial products in the US
- Hikma to get exclusive rights to commercialize in the US & is responsible for registering the products with the US FDA
- Denosumab is a human mAb & is used for the treatment of osteoporosis and fractures due to bone metastasis which is currently in P-I & III clinical studies. The product is marketed under two brands i.e., Prolia (60mg/ml solution for inj. in PFS) & Xgeva (120mg/1,7 ml solution for inj. in a vial)
Ref: Hikma | Image: Hikma
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com